Late last week, the Senate Judiciary Committee announced the formation of an Intellectual Property (IP) Subcommittee.

In Momenta Pharmaceuticals, Inc. v. Bristol-Myers Squibb Co. (here), the Federal Circuit was poised to explore the level of biosimilar legwork that could satisfy Article III ...

In Mylan Pharmaceuticals Inc. v. Research Corp. Technologies, Inc., (here) the Federal Circuit held that parties joined to an IPR petition have a statutory right of appeal under 35 U.S.C. § 319

So I mean, a patent litigation can be very expensive running through trial, running into multiple millions of dollars.

As previously discussed, the Patent Trial & Appeal Board (PTAB) is now reconsidering its issue joinder practices

The Defendants declined to file another 101 motion and represented that it would not file it again until after claim construction.

Last September, the Patent Trial & Appeal Board (PTAB) held that the advanced state of a district court proceeding militated in favor of denying a petition for IPR in accordance

Post SAS, there are fewer exceptions to IPR estoppel. Indeed, the absence of partial institutions has led to many courts finding the "reasonably could have raised" ...

After Octane Fitness, district courts "may determine whether a case is ‘exceptional' in the case-by-case exercise of their discretion, considering the totality of the circumstances."

Patent pools and groupings of standard essential patents (SEPs) facilitate one-stop shopping of patent licensees.

Today, the USPTO announced revised guidance for subject matter eligibility under 35 U.S.C. § 101 (here). The USPTO also announced guidance on the application of 35 U.S.C.

The Patent Trial & Appeal Board (PTAB) stole much of the 2018 patent law spotlight. From landmark Supreme Court decisions such as Oil States and SAS Institute ...

As we close out 2018, there may be some hope on the horizon for those confounded by the current state of patent eligibility determinations under 35 U.S.C. § 101.

Scott McKeown, Ropes & Gray IP litigation partner and chair of the firm's Patent Trial and Appeal Board (PTAB) group, examines how some recent changes at the PTAB will benefit patent owners.

Scott McKeown, Ropes & Gray IP litigation partner and chair of the firm's Patent Trial and Appeal Board (PTAB) group, examines how some recent changes at the PTAB will benefit patent owners.